GlassScriptPhysician profile
Abhay Malhotra
NPI 1073527859
$11,135.88
in general payments reported to CMS, 2019-2025
38 companies · $998 in 2025
The $998 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,548 · 2020: $1,160 · 2021: $2,699 · 2022: $1,680 · 2023: $1,740 · 2024: $1,310 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,022 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,021.62 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,117.33 | 2020-2025 | Cardiomems, Jot Dx |
| Novartis Pharmaceuticals Corporation | $964.49 | 2019-2025 | |
| Amgen INC. | $951.35 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $872.72 | 2019-2025 | Breztri, Wainua, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $867.29 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $837.41 | 2021-2025 | Verquvo |
| Glaxosmithkline, LLC. | $765.24 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $626.85 | 2019-2024 | Xarelto |
| Pfizer INC. | $610.50 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $573.31 | 2019-2024 | |
| Boston Scientific Corporation | $408.43 | 2020-2025 | Avvigo Guidance System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $354.38 | 2019-2025 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $353.96 | 2019-2022 | |
| Medtronic, INC. | $265.55 | 2021-2025 | Micra, Cobalt Dr Mri Surescan |
| Esperion Therapeutics, INC. | $264.48 | 2020-2025 | Nexletol |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $243.88 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $144.35 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.33 | 2020-2024 | Lifevest |
| Novo Nordisk INC | $105.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Biotronik INC. | $87.42 | 2025 | Acticor 7 Vr-T Dx, Biomonitor |
| Gilead Sciences, INC. | $83.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $79.53 | 2019-2021 | |
| Intuitive Surgical, INC. | $75.95 | 2023 | Da Vinci Surgical System |
| Chiesi USA, INC. | $59.04 | 2021-2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $46.10 | 2024 | Uptravi, Opsumit |
| Astellas Pharma US INC | $33.23 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $25.82 | 2024 | |
| Cmp Pharma, INC. | $22.74 | 2022 | |
| Vifor Pharma, INC. | $21.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.27 | 2021 | |
| Lundbeck LLC | $20.55 | 2019 | |
| Philips North America LLC | $19.83 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Heartflow, INC. | $19.58 | 2022 | |
| Bridgebio Pharma, INC. | $19.54 | 2025 | Attruby |
| Shield Therapeutics INC | $18.76 | 2025 | |
| Irhythm Technologies, INC. | $18.43 | 2023 | Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $18.38 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhay Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.